RecruitingNCT07144306

AI-Driven Early Detection of Skin Cancer


Sponsor

Nuvana Healthcare LTD

Enrollment

100 participants

Start Date

Oct 1, 2025

Study Type

OBSERVATIONAL

Conditions

Summary

This study evaluates the feasibility and accuracy of an AI-powered mobile platform (NuvanaDx) for early detection of skin cancer, including melanoma, using smartphone-based imaging. The platform is designed to improve access to early diagnosis, reduce waiting times, and support triage into appropriate care pathways.


Eligibility

Min Age: 18 Months

Plain Language Summary

Simplified for easier understanding

This study is testing whether an artificial intelligence (AI) tool can help doctors detect skin cancer earlier and more accurately by analyzing photos of suspicious skin lesions. The goal is to see if AI-assisted evaluation improves early detection. **You may be eligible if...** - You are 18 years or older - You have a skin lesion that looks suspicious for cancer - You are able to give informed consent to participate **You may NOT be eligible if...** - You are unable to provide informed consent - The photos of your skin lesion are too poor in quality for AI analysis Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSmartphone-based AI skin lesion analysis (NuvanaDx platform).

Smartphone-based AI skin lesion analysis (NuvanaDx platform).


Locations(1)

Nuvana Healthcare Ltd

London, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07144306


Related Trials